Table 1 Clinicopathological features of breast cancer patients studied
From: The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer
n=96 | Prior to chemotherapy | After chemotherapy | ||
|---|---|---|---|---|
Tumour size | 1,5-13 cm | 0,3-14 cm | ||
| Â | cT1 | 1 (1%) | ypT0 | 6 (6%) |
| Â | -a | Â | ypT1 | 20 (21%) |
| Â | -b | Â | -a | 2 |
| Â | -c | 1 | -b | 11 |
| Â | cT2 | 25 (26%) | -c | 7 |
| Â | cT3 | 22 (23%) | ypT2 | 31 (32%) |
| Â | cT4 | 41 (43%) | ypT3 | 24 (25%) |
| Â | -b | 19 | ypT4 | 7 (7%) |
| Â | -d | 22 | -b | 6 |
| Â | NA | 7 (7%) | -d | 1 |
| Â | Â | Â | No surgery | 8 (9%) |
Lymph node status | cN0 | 10 (11%) | pN0 | 25 (26%) |
| Â | cN1 | 62 (64%) | pN1 | 27 (28%) |
| Â | cN2 | Â | pN2 | 12 (12%) |
| Â | cN3 | 3 (3%) | pN3 | 14 (15%) |
| Â | Â | Â | No surgery | 8 (9%) |
| Â | NA | 21 (22%) | NA | 10 (10%) |
ER status | Positive | 68 (71%) | Positive | 59 (62%) |
| Â | Negative | 25 (26%) | Negative | 16 (17%) |
| Â | NA | 3 (3%) | NA | 21 (21%) |
| Â | Â | Â | ypT0, no surgery | Â |
PR status | Positive | 59 (62%) | Positive | 46 (48%) |
| Â | Negative | 34 (35%) | Negative | 29 (31%) |
| Â | NA | 3 (3%) | NA | 21 (21%) |
| Â | Â | Â | ypT0, no surgery | Â |
HER2 status | Positive | 28 (29%) | Positive | 18 (19%) |
| Â | Negative | 65 (68%) | Negative | 57 (60%) |
| Â | NA | 3 (3%) | NA | 21 (21%) |
| Â | Â | Â | ypT0, no surgery | Â |
Ki67 status | 0 | 2 (2%) | 0 | 22 (28%) |
| Â | 1 (0-1%) | 12 (15%) | 1 | 21 (27%) |
| Â | 2 (1-5%) | 19 (23%) | 2 | 11 (14%) |
| Â | 3 (5-10%) | 13 (16%) | 3 | 3 (4%) |
| Â | 4 (10-15%) | 6 (7%) | 4 | 1 (1%) |
| Â | 5 (15-20%) | 4 (5%) | 5 | 6 (8%) |
| Â | 6 (20-33%) | 2 (2%) | 6 | 1 (1%) |
| Â | 7 (33-50%) | 4 (5%) | 7 | 2 (3%) |
| Â | 8 (50-66%) | 1 (1%) | 8 | 0 (0%) |
| Â | 9 (66-80%) | 3 (4%) | 9 | 3 (4%) |
| Â | 10 (80-100%) | 1 (1%) | 10 | 2 (3%) |
| Â | NA | 14 (17%) | NA | 7 (9%) |
|  | ∑ | 64+17 (100%) | ∑ | 64+15 (100%) |